afternoon, has I proud the Good year-over-year. Total product ago from high of quarter Stephanie. XXXX Codexis revenue am XX%. than you, of report gross that of more margin to year revenue, quarter tripled another XXX% Thank grew third everyone. and reached a a Product exceptional operational for performance. delivered new
diversify Over the continue of revenue, past seven $XXX,XXX million base XX contributed $X quarter, over over we customers customer to who with our revenue. whom in in
treatment partnerships the In the we and on demonstrated in sale remain This insufficiency. X the with for track to our we market, this HiFi entered step-out their proprietary have out therapeutic progress product Nestlé of Pfizer growth the million. and the $XX which clinic space. pancreatic the exocrine is Health with Science Codexis the trials. Codex® therapeutic second far the Our August disclosed the driven approximately late food this June to in manufacture were Science the we thrilled quarter, our Life business coming have and purchase company and this co-owned clinical history. from with orders Sustainable orders execute large of Polymerase, this stage for sector. enzymes received only And was to Biotherapeutics COVID-XX of pleased business, very products sitagliptin sales success reach our clinical CDX-XXXX, demonstrated in the in story of to our designed market DNA excellent upcoming represents largest we strongly aggregate of to commercial other one manufacturing Tools Manufacturing generic business are annual Phase The sustainable we antiviral where And by faster-to-market for we is custom first also quarter, enzyme in for ourselves candidate. a from This positioned chapter
is which Nestlé of CDX-XXXX, Health Science phenylketonuria. being fully the first for licensed with treatment The
accelerating majority enable the Our core results to we've And market the discover cost value the a capital Sustainable yields, company and capital and where Codexis market decreased markets enzymes is diverse Manufacturing commercialize also end showcase been our undeniable revenues. in reduced as pharmaceutical parallel. engineered continued across for ability drive higher is large using chemistry, enzymes. this energy high-performance sustainability progress engineering. have enzymes waste established dramatically which continues traditional, enzyme our Compared And manufacturing, segments robust usage Codexis’ reduce the to leader to speed platform to Codexis’ in reliably represent to enabling novel customers the of manufacturing products. to of ability lower growing is and sustainable engineering meaningfully the of constantly target intensive their non-enzymatic processes be increase generation. our creating Small Codexis. molecule while for and our needs CodeEvolver and inefficient, enzyme
their adopt stage, manufacturing partnered a for Codexis, have their The novel orders companies to for and manufactured therapeutic size. antiviral disclosed Pfizer the them for We COVID-XX, purchase with enzymes largest XX world represents given for Codexis of enzyme milestone Codexis clinical we their historic help XX candidate in large APIs. install proprietary the pharmaceutical a
the our manufacturing In us test, up addition, our and quickly produce this Pfizer magnitude. and enzyme ability business an at with the this to necessary of orders came of chain unprecedented to speed. giving scale put these from the supply to prove fulfill Furthermore, the orders opportunity pace fruition to orders also to
multi in have for Merck on work wish the we their to Pfizer treatment the done of in to for on authorization. and engineering and are Molnupiravir. COVID potential a this note front, of enzyme we conclusion critical their be clinical program COVID that COVID antiviral manufacturing patients, drug design with We supporting them cascade well Also, proud collaboration the some we impressive enzyme antiviral regulatory
engineered high-performance to CodeEvolver enzymes, decided with could non-enzymatic have Merck Authorization but possible eventually It a Use we GenX branded build product cost our knowledge a to anticipated goes a supplies The by However, is launch drug, that so the with partner for Codexis to be off a their Merck when no patent. Emergency process. life has process Merck a anytime enzymes switch stakeholders of of to plans key cycle including to position throughout do savings provided soon.
As most call reduced on an manufacture for know cost that their we blockbuster the to enzyme the significantly in drug API sitagliptin, of their developed Merck you diabetes Januvia.
Our sitagliptin for has product us important revenue nearly an decade. generator enzyme been a over
supply our growing pending patent produce that first With help generic manufacturers With enzyme the end, supply Januvia, low its from of to extended positioned our them two XXXX. contract third lower proprietary well agreed into during them we enzyme capability extend has the their license generic generic enzyme, of sitagliptin our product driven business agreements pleased and to In sitagliptin through their for multi-year cost with enabling the cost our to manufacturing chapter. sitagliptin. Codexis to on are the for quarter, to decision enzyme the still. self-produce exploration to we our we are this established process of sitagliptin. capitalize for demand long-standing even install Merck, the we To to case end be And Almelo to
produced marketplace. establish global a generic, low-cost for in RCX supply Pharma to of for success the enables drug RCX chain sitagliptin. integrated, to this Almelo Adding channels partners relationships with position the leveraging downstream coming expertise sitagliptin responsible the this collaboration fully competitive, part uniquely product to market of is partnership As
industry enzymes. we've chemical expanding especially sustainably host prevent products pharma to glass other is the of Working light-stable be enzymes to of leveraged advanced designing technology By the hop enzymes the beer acid. have biochemically light enzymes In reach of few packaged a typically These products more quickly. to also novel manufacturing, know in manufacturer the manufacturing beverage enzyme hop beers wide with is July, of past as And may Kalsec’s expanded hurdles of addition degradation you or cleaner produced, CodeEvolver in canned food the in product Kalsec, collaboration the utilizing industrial and our provides range innovation applications, skunky for a dark rather Codexis’ leading conventional In hops. a than been to well IPA’s, producer other without character stable to the that enables that with market declaration. team, industries, potential The including means, and catalytic bio what hoppy years, the announced clear pharma for ingredients, closely green lower to a develop of glass light-struck of we hops an a risk natural beverage engineered Beers, proprietary hop bottled acid enabling degradation. production platform beverage enzyme to label than rapid the we development be timelines final as a formation to need beer. regulatory shorter enabling engineering more our a and as food products.
Allulose out unique move new self-affirmation of the of achieving what newly for sector In as DOLCIA revenues, we scratches otherwise through about we food addition these as are from & vertical, XXXX sales, opportunities product M remain this Kalsec and in strong our the the applications. generally pleased milestone growing see engineered Lyle’s, to our well to expect this Tate nutrition as PRIMA® enthusiastic momentum agreement for enzyme food and from possible the expanding Kalsec and in GRAS surface enzymes. Rounding partnership sweeteners, both enzyme. the we growing to peak also only quarter for for recognized is TASTEVA® boding Stevia We food each our the safe, using third with known commercialized
customers. and life and opportunity is can enable more. sequencing, next-generation Codexis Another applications, marketed RNA engineered The molecular the high can develop improvements and margin the synthesis, Codexis rapid science market DNA its in diagnostics, market biosensor in prospects. us opportunity enzymes is multiple be cycles for market. growth also very tools above that The to products attractive to and given average commercialization affords
engineered addition the In for highly customize specific enzymes, we to partners.
tools based marketing, DNA third year, polymerase, DNA broad to quarter, polymerase, the past Reverse Codex we our RNA science In first HiFi sale Codex Transcriptase. enzymes new developed life the polymerase. HiCap for of record and Codex Codex pleased HiFi we've Over were commercial three customer
the sequencing and we highest in being DNA by all is the that product. HiFi our RNA made RNA Earlier capping customers Codex proud product first pharmaceutical are of reduce for enabling the the is engineered stabilizing ramp to strong polymerase year, Our manufacturing this customers interest to existing sales capping sales in its tested Codex polymerase analysis results competitive provide for tested Codex clinical demonstrates the applications. have stage remains for processes. to HiCap science we significantly HiFi multiple Codex fidelity use enables to in of critical and new polymerase amount several enzyme polymerases future use begun customers HiCap life polymerase RNA that use. higher of and reagent for to dramatically commercial We messenger efficiency, DNA the important, next-gen
In enzyme proprietary addition, unwanted, mRNA which simplifies downstream yield increases stranded, production of of decreases impurities, and our production the the double product.
stability. been Our diagnostic third enzymes Transcriptase, science incumbent both for performance applications. Reverse has detection. with reading, most well engineered enzymes. resistance One our been of tools temperatures and their RT–PCR above to current improved sequencing low the to and limitation Codex need has sensitivity RNA heated the in for is, is use transcriptase reverse be It RNA-based of enzyme, at specifically inhibitor life an developed samples versus get disease in accurate thermal melt To tolerance
Transcriptase Reverse at Codex thrives high Our temperatures.
Reverse two false also have interfere robust result. samples time the in parameters doing ensuring thereby tested negatives enzyme our a inhibitor reducing from turnaround enzyme the Codex its needed that increased resistance, a found engineered these prevent results reducing sensitive the with components for and make or for diagnostic other much We more job. and not do Transcriptase Together, enzyme
strides, solution to designed is their to and to a synthesis product performance The CodeEvolver to Assemblies is the cost-effective MAI’s access scaling dramatic from we current synthesizing DNA. and to Codexis viable, encouraged improvements between early is performance team process enzymatic a reality, disruptive manufacturing engineering leveraging launch a by by the tested to approach are going gene diagnostic for for commercial date. platform manufacturing process parallel, feedback broader the Molecular closer enzymes to long and Molecular power making users building DNA In chain accelerate of next also great commercially who make chemical market. month. deliver are into Assemblies and on differentiated We And applications over Codexis the track to partnership have DNA. bringing
us have partnership shareholder. $X equity our second Given our Molecular and to the stepping stake Assemblies we in become in increase their investing confidence to decided million up largest
to and our SynBio be strategic the life demand Innovation supply DNA access leveraging to life continue synthesis as Molecular from in partner experience downstream tool invested partnered for marketplace enzyme become custom Capital, to $X Rounding science we engineering to applications exciting Casdin Accelerator, Our the sector fast-growing moves. programs via enzyme industry. new a Assemblies. for value It's strong the shareholder and these well the out has capabilities engineering in million in sciences within second-generation
Our currently running can synthesis, market. oligonucleotide partnered life genomics, dedicated discover biosensors, strategy heavily in this in Codexis. CodeEvolver enzyme another is biotherapeutics our The and engineering bring novel teams multiple to growing of dependent growth science advantages industry develop field are and to solidifies Leveraging that for and programs the belief value CodeEvolver more. exciting the
a Here biologics we and candidates. and are oral high-value pipeline gene advancing of rapidly building therapy
lipase in discovered that for recently dose exocrine EPI for replacement to our a is by to the development GI the cancer, programs, pancreatic limited fibrosis. engineered of lipase early-stage to programs pancreatitis, for orally Just reached the care value small study CDX-XXXX, of deficiencies. pancreatic traditional care pancreatic of precisely two clinical for initiated a and condition in We enzyme celiac pancreatic The having of including insufficiency. protease debilitating GI therapies only that few standard years and order conditions By CDX-XXXX replacement in with Crohn's enzyme our pipeline. function, are pipeline thrilled their the holding our disease, candidate for announce a disease, Phase select breakthrough second for stage due we tract we caused this efficacy limitations assets demonstrated are component. an PERTs, of enhanced that XX-fold or a cystic engineering treatment instability dozen active tolerance at absorption biotherapeutic were programs condition PERT. acid therapy administered the Codexis. pancreatic impair lower X for very into has of was current and their in deeper Today, GI stability is over the preclinical than stomach recovery intestines, ago, overcome CDX-XXXX equivalent CodeEvolver of clinical have trials resistance we enhance had standard to increasingly a
single escalation advance are partnership patients design trial Health with We our volunteers Nestlé series owned early in by into EPI. excited study clinical single a development. of healthy comprises of dose of clinical dose CDX-XXXX, to equally followed Science candidates in and The dose a trials from the proof first concept multiple
entirety and and the making Nestlé as news our other CDX-XXXX, self-funded oral While programs is and we their pipeline Three advancing the big are are biologic development. co-owned two across segment well. progress in of our all research preclinical
Takeda on have partnership an enable the also is gene genes trans diseases. which We impressive next-generation rare program candidates for focused engineering with therapy four to Pharmaceuticals, differentiated
In the and for discovery we Codexis embarked other great targeting year. addition this disorders. self-funded to Takeda, rare by on made with genes being programs, see so programs partnered to successfully recently have improved progress trans expanding team, It's the biotherapeutics the advancing
hand detail. results call financial now more me through Let take Ross to you our the in over to
